Free Trial

Canopy Growth (TSE:WEED) Price Target Cut to C$3.20 by Analysts at ATB Capital

Canopy Growth logo with Medical background

Canopy Growth (TSE:WEED - Free Report) had its price objective cut by ATB Capital from C$4.00 to C$3.20 in a report published on Monday morning,BayStreet.CA reports. They currently have an underperform rating on the stock.

Separately, Canaccord Genuity Group decreased their price objective on Canopy Growth from C$2.50 to C$1.50 and set a "sell" rating for the company in a report on Monday. Four equities research analysts have rated the stock with a sell rating and one has given a hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average price target of C$5.40.

Check Out Our Latest Analysis on Canopy Growth

Canopy Growth Price Performance

Shares of WEED stock remained flat at C$2.68 on Monday. The stock had a trading volume of 909,932 shares, compared to its average volume of 1,844,812. The stock has a market capitalization of C$431.13 million, a price-to-earnings ratio of -0.39, a P/E/G ratio of -0.01 and a beta of 1.79. The company's fifty day simple moving average is C$3.67 and its 200-day simple moving average is C$5.79. The company has a current ratio of 1.39, a quick ratio of 2.32 and a debt-to-equity ratio of 120.38. Canopy Growth has a fifty-two week low of C$2.50 and a fifty-two week high of C$20.50.

Canopy Growth Company Profile

(Get Free Report)

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names.

Further Reading

Analyst Recommendations for Canopy Growth (TSE:WEED)

Should You Invest $1,000 in Canopy Growth Right Now?

Before you consider Canopy Growth, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.

While Canopy Growth currently has a "Strong Sell" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

As Wall Street's 2025 predictions roll in, Goldman Sachs is focusing on manufacturing, energy, and domestic producers as key sectors for growth.

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines